Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

von Minckwitz, Gϋnter; Huang, Chiun‐Sheng; S. Mano, Max; Loibl, Sibylle; P. Mamounas, Eleftherios; Untch, Michael; Wolmark, Norman; Rastogi, Priya; Schneeweiß, Andreas; Redondo, Andrés; Holger Fischer, Hans; Jacot, William; Conlin, Alison; Arce-Salinas, Claudia; Wapnir, Irene; Jackisch, Christian; P. DiGiovanna, Michael; A. Fasching, Peter; Crown, John; Wülfing, P; Shao, Zhimin; Rota Caremoli, Elena; Wu, Haiyan; H. Lam, Lisa; Tesarowski, David; C. Smitt, Melanie; Douthwaite, Hannah; Mui Singel, Stina; E. Geyer, Charles

doi:10.1056/nejmoa1814017

Public

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Published in New England Journal of Medicine • Dec 5, 2018

Authors:

Gϋnter von Minckwitz

Chiun‐Sheng Huang

Max S. Mano

Abstract

BACKGROUND: Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)-targeted therapy have a worse prognosis than those who have no residual cancer. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate of tra...

Subject

Trastuzumab emtansine

Trastuzumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!